Loratadine

證據等級: L5

預測適應症: 5 個

Loratadine: From Allergic Rhinitis to Pharyngitis

One-Sentence Summary

Loratadine is a second-generation, non-sedating H1 antihistamine widely established for the treatment of allergic rhinitis and chronic urticaria. The TxGNN model predicts it may be effective for Pharyngitis, with 2 clinical trials and 7 publications providing contextual supporting evidence.

Note: TxGNN prediction scores were not returned for this evaluation run (all scores recorded as 0.0). The ranking order reflects the model’s relative prioritisation, but numeric scores should be treated as unavailable pending pipeline review.

Quick Overview

Item	Content
Original Indication	Allergic rhinitis and chronic urticaria (licence detail records not populated in this dataset)
Predicted New Indication	Pharyngitis
TxGNN Prediction Score	Not available (score data gap in this run)
Evidence Level	L3
Malaysia Market Status	✓ Marketed (已上市)
Number of Registrations	56
Recommended Decision	Hold (Research Question)

Why Is This Prediction Reasonable?

Loratadine is a long-acting, selective peripheral H1 receptor antagonist — the prototypical second-generation antihistamine. By competitively blocking histamine H1 receptors, it prevents the downstream effects of histamine release: vasodilation, increased vascular permeability, stimulation of sensory nerve endings, and mucus hypersecretion. Unlike first-generation antihistamines, it does not readily cross the blood–brain barrier, which explains its non-sedating profile. Its active metabolite, desloratadine, shares these properties and contributes to its sustained duration of action.

The mechanistic link between Loratadine’s established indication (allergic rhinitis) and pharyngitis is anatomically plausible. Both conditions involve inflammation of contiguous upper respiratory mucosa, and in allergic or post-nasal drip-associated pharyngitis, histamine released from mucosal mast cells contributes to local swelling, hypersecretion, and the sensation of throat irritation. H1 blockade could theoretically attenuate these symptoms, particularly in patients whose pharyngitis has an allergic or reactive component.

However, the mechanistic relevance is indirect and context-dependent. The large majority of acute pharyngitis cases are driven by viral (rhinovirus, adenovirus, coronavirus) or bacterial (Streptococcus pyogenes) infection, where histamine-mediated inflammation is a secondary rather than primary pathological driver. Clinical benefit from Loratadine monotherapy in this setting would therefore be expected to be modest and symptomatic. This is consistent with the evidence landscape: the clinical trials identified involve Loratadine as a component of combination products targeting upper respiratory symptoms broadly, not as a stand-alone pharyngitis therapy.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06531707	Phase 3	Recruiting	177	Randomised, double-blind, multi-centre trial comparing an Ibuprofen/Loratadine fixed-dose combination vs each monotherapy for symptomatic treatment of the common cold (encompassing pharyngeal symptoms); results not yet available
NCT05275933	Phase 2/3	Completed	93	Assessed Lian Hua Qing Wen (TCM) capsules as adjuvant therapy in mild COVID-19 home recovery in Singapore; Loratadine is not the investigational agent — relevance to pharyngitis repurposing is minimal

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28441993	2017	RCT	Allergy and Asthma Proceedings	Randomised, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis; demonstrates H1 antihistamine efficacy for upper-airway allergic inflammation — the mechanistic class relevant to pharyngitis
8621843	1996	RCT	J Allergy Clin Immunol	Fluticasone propionate vs loratadine 10 mg once daily in 240 adolescents with ragweed-induced seasonal AR over 4 weeks; loratadine reduced both nasal and ocular symptom scores significantly vs baseline
12642846	2003	RCT	J Allergy Clin Immunol	Randomised double-blind trial of desloratadine (Loratadine’s principal active metabolite) in perennial allergic rhinitis; supports H1 blockade as a strategy for managing year-round upper-airway mucosal inflammation
11277962	2001	RCT	Int J Dermatology	Once-daily desloratadine vs placebo for chronic idiopathic urticaria; confirms anti-inflammatory and antipruritic efficacy of the loratadine/desloratadine drug class across histamine-mediated tissue reactions
12962522	2003	Review	Drugs	Comprehensive review of desloratadine efficacy in SAR, perennial AR, and chronic idiopathic urticaria; rapid onset, full 24-hour dosing coverage, and sustained anti-allergic effect across indications
9806113	1998	Review	Drugs	Review of mometasone furoate for allergic rhinitis; loratadine cited as an active comparator, underscoring its reference standard role in upper respiratory allergy management
19821542	2009	Consumer Guide	Consumer Reports	OTC drug comparison guide; loratadine identified as a recommended non-sedating antihistamine for upper respiratory allergy relief — indirect confirmation of its established real-world positioning

Malaysia Market Information

Loratadine holds 56 registered products in Malaysia (market status: ✓ Marketed). The detailed individual licence records — including product names, dosage forms, manufacturers, and approved indication text — were not populated in this Evidence Pack.

Please consult the NPRA e-Register at https://www.npra.gov.my for complete registration details across all 56 product authorisations.

Safety Considerations

Please refer to the package insert for safety information. Detailed warnings, contraindications, and drug interaction data were not available in this Evidence Pack (Data Gaps DG001 and DG002). Remediation steps are noted in the Next Steps section below.

Conclusion and Next Steps

Decision: Hold (Research Question)

Rationale: While the mechanistic basis for Loratadine in pharyngitis is biologically plausible, histamine plays only a secondary role in most pharyngitis cases, and no clinical trials have directly investigated Loratadine monotherapy for pharyngitis as a primary endpoint. The identified trials target broader upper respiratory tract symptoms using combination products, and the evidence level (L3) does not yet support a direct repurposing claim.

To proceed, the following is needed:

Resolve Data Gap DG001: Retrieve NPRA-registered product package inserts (via NPRA official website PDF download) to obtain approved indications, key warnings, and contraindications
Resolve Data Gap DG002: Query the DrugBank API (DB00455) to confirm Loratadine’s full mechanism of action, pharmacokinetics, and toxicity profile
Clarify TxGNN score output: All five predicted indications returned a score of 0.0 in this run — investigate whether this reflects a pipeline serialisation issue or genuine model output, and rerun if necessary
Commission a targeted evidence review: Conduct a systematic literature search specifically for antihistamine monotherapy in viral pharyngitis and allergic pharyngitis (distinct from allergic rhinitis), to determine whether direct clinical evidence exists
Populate NPRA licence data: Query the NPRA e-Register to retrieve product names, dosage forms, and approved indication text for the 56 registered products, enabling a complete Malaysia Market Information table
Consider evaluating Rank 4 (Common Cold) in parallel: That indication has stronger direct evidence (Phase 3 RCT ongoing, 1989 RCT with Loratadine + pseudoephedrine, L3 evidence level) and a “Proceed with Guardrails” recommendation — it may be a more actionable near-term repurposing candidate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.